The European Vasculitis Society 2016 meeting report
The 2016 European Vasculitis Society (EUVAS) meeting, held in Leiden, the Netherlands, was centered around phenotypic subtyping in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). There were parallel meetings of the EUVAS petals, which here report on disease assessment; databa...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Conference item |
| Published: |
Elsevier
2017
|
| _version_ | 1826305177126174720 |
|---|---|
| author | Bajema, IM Bruijn, JA Casian, A Cid, MC Csernok, E Van Daalen, E Harper, L Hauser, T Little, MA Luqmani, RA Mahr, A Ponte, C Salama, A Segelmark, M Suzuki, K Sznajd, J Teng, YKO Vaglio, A Westman, K Jayne, D |
| author_facet | Bajema, IM Bruijn, JA Casian, A Cid, MC Csernok, E Van Daalen, E Harper, L Hauser, T Little, MA Luqmani, RA Mahr, A Ponte, C Salama, A Segelmark, M Suzuki, K Sznajd, J Teng, YKO Vaglio, A Westman, K Jayne, D |
| author_sort | Bajema, IM |
| collection | OXFORD |
| description | The 2016 European Vasculitis Society (EUVAS) meeting, held in Leiden, the Netherlands, was centered around phenotypic subtyping in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). There were parallel meetings of the EUVAS petals, which here report on disease assessment; database; and long-term follow-up, registries, genetics, histology, biomarker studies, and clinical trials. Studies currently conducted will improve our ability to discriminate between different forms of vasculitis. In a project that involves the 10-year follow-up of AAV patients, we are working on retrieving data on patient and renal survival, relapse rate, the cumulative incidence of malignancies, and comorbidities. Across Europe, several vasculitis registries were developed covering over 10,000 registered patients. In the near future, these registries will facilitate clinical research in AAV on a scale hitherto unknown. Current studies on the genetic background of AAV will explore the potential prognostic significance of genetic markers and further refine genetic associations with distinct disease subsets. The histopathological classification of ANCA-associated glomerulonephritis is currently evaluated in light of data coming out of a large international validation study. In our continuous search for biomarkers to predict clinical outcome, promising new markers are important subjects of current research. Over the last 2 decades, a host of clinical trials have provided evidence for refinement of therapeutic regimens. We give an overview of clinical trials currently under development, and consider refractory vasculitis in detail. The goal of EUVAS is to stimulate ongoing research in clinical, serological, and histological management and techniques for patients with systemic vasculitis, with an outlook on the applicability for clinical trials. |
| first_indexed | 2024-03-07T06:28:55Z |
| format | Conference item |
| id | oxford-uuid:f547d8bf-10fa-4d3a-823e-3305c3efa0c8 |
| institution | University of Oxford |
| last_indexed | 2024-03-07T06:28:55Z |
| publishDate | 2017 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:f547d8bf-10fa-4d3a-823e-3305c3efa0c82022-03-27T12:26:13ZThe European Vasculitis Society 2016 meeting reportConference itemhttp://purl.org/coar/resource_type/c_5794uuid:f547d8bf-10fa-4d3a-823e-3305c3efa0c8Symplectic Elements at OxfordElsevier2017Bajema, IMBruijn, JACasian, ACid, MCCsernok, EVan Daalen, EHarper, LHauser, TLittle, MALuqmani, RAMahr, APonte, CSalama, ASegelmark, MSuzuki, KSznajd, JTeng, YKOVaglio, AWestman, KJayne, DThe 2016 European Vasculitis Society (EUVAS) meeting, held in Leiden, the Netherlands, was centered around phenotypic subtyping in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). There were parallel meetings of the EUVAS petals, which here report on disease assessment; database; and long-term follow-up, registries, genetics, histology, biomarker studies, and clinical trials. Studies currently conducted will improve our ability to discriminate between different forms of vasculitis. In a project that involves the 10-year follow-up of AAV patients, we are working on retrieving data on patient and renal survival, relapse rate, the cumulative incidence of malignancies, and comorbidities. Across Europe, several vasculitis registries were developed covering over 10,000 registered patients. In the near future, these registries will facilitate clinical research in AAV on a scale hitherto unknown. Current studies on the genetic background of AAV will explore the potential prognostic significance of genetic markers and further refine genetic associations with distinct disease subsets. The histopathological classification of ANCA-associated glomerulonephritis is currently evaluated in light of data coming out of a large international validation study. In our continuous search for biomarkers to predict clinical outcome, promising new markers are important subjects of current research. Over the last 2 decades, a host of clinical trials have provided evidence for refinement of therapeutic regimens. We give an overview of clinical trials currently under development, and consider refractory vasculitis in detail. The goal of EUVAS is to stimulate ongoing research in clinical, serological, and histological management and techniques for patients with systemic vasculitis, with an outlook on the applicability for clinical trials. |
| spellingShingle | Bajema, IM Bruijn, JA Casian, A Cid, MC Csernok, E Van Daalen, E Harper, L Hauser, T Little, MA Luqmani, RA Mahr, A Ponte, C Salama, A Segelmark, M Suzuki, K Sznajd, J Teng, YKO Vaglio, A Westman, K Jayne, D The European Vasculitis Society 2016 meeting report |
| title | The European Vasculitis Society 2016 meeting report |
| title_full | The European Vasculitis Society 2016 meeting report |
| title_fullStr | The European Vasculitis Society 2016 meeting report |
| title_full_unstemmed | The European Vasculitis Society 2016 meeting report |
| title_short | The European Vasculitis Society 2016 meeting report |
| title_sort | european vasculitis society 2016 meeting report |
| work_keys_str_mv | AT bajemaim theeuropeanvasculitissociety2016meetingreport AT bruijnja theeuropeanvasculitissociety2016meetingreport AT casiana theeuropeanvasculitissociety2016meetingreport AT cidmc theeuropeanvasculitissociety2016meetingreport AT csernoke theeuropeanvasculitissociety2016meetingreport AT vandaalene theeuropeanvasculitissociety2016meetingreport AT harperl theeuropeanvasculitissociety2016meetingreport AT hausert theeuropeanvasculitissociety2016meetingreport AT littlema theeuropeanvasculitissociety2016meetingreport AT luqmanira theeuropeanvasculitissociety2016meetingreport AT mahra theeuropeanvasculitissociety2016meetingreport AT pontec theeuropeanvasculitissociety2016meetingreport AT salamaa theeuropeanvasculitissociety2016meetingreport AT segelmarkm theeuropeanvasculitissociety2016meetingreport AT suzukik theeuropeanvasculitissociety2016meetingreport AT sznajdj theeuropeanvasculitissociety2016meetingreport AT tengyko theeuropeanvasculitissociety2016meetingreport AT vaglioa theeuropeanvasculitissociety2016meetingreport AT westmank theeuropeanvasculitissociety2016meetingreport AT jayned theeuropeanvasculitissociety2016meetingreport AT bajemaim europeanvasculitissociety2016meetingreport AT bruijnja europeanvasculitissociety2016meetingreport AT casiana europeanvasculitissociety2016meetingreport AT cidmc europeanvasculitissociety2016meetingreport AT csernoke europeanvasculitissociety2016meetingreport AT vandaalene europeanvasculitissociety2016meetingreport AT harperl europeanvasculitissociety2016meetingreport AT hausert europeanvasculitissociety2016meetingreport AT littlema europeanvasculitissociety2016meetingreport AT luqmanira europeanvasculitissociety2016meetingreport AT mahra europeanvasculitissociety2016meetingreport AT pontec europeanvasculitissociety2016meetingreport AT salamaa europeanvasculitissociety2016meetingreport AT segelmarkm europeanvasculitissociety2016meetingreport AT suzukik europeanvasculitissociety2016meetingreport AT sznajdj europeanvasculitissociety2016meetingreport AT tengyko europeanvasculitissociety2016meetingreport AT vaglioa europeanvasculitissociety2016meetingreport AT westmank europeanvasculitissociety2016meetingreport AT jayned europeanvasculitissociety2016meetingreport |